Last reviewed · How we verify
Alhydrogel
At a glance
| Generic name | Alhydrogel |
|---|---|
| Also known as | Aluminum hydroxide adjuvant 2% |
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. (PHASE3)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alhydrogel CI brief — competitive landscape report
- Alhydrogel updates RSS · CI watch RSS
- University of Oxford portfolio CI